CD38 and Miyoshi myopathy: The approvals and introduction in daily practice of immunomodulatory agents (IMiDS), novel generation proteasome inhibitors (PI), and anti-CD38 monoclonal antibodies have provided effective therapeutic options, which give patients with relapsed or refractory MM the prospect of a prolongation of overall survival (OS) and progression-free survival (PFS) [2, 3].